{"id":"olmesartan-medoxomil-tablets-high-dose","safety":{"commonSideEffects":[{"rate":"3-10%","effect":"Dizziness"},{"rate":"2-5%","effect":"Headache"},{"rate":"2-5%","effect":"Fatigue"},{"rate":"2-5%","effect":"Cough"},{"rate":"2-5%","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL1200692","moleculeType":"Small molecule","molecularWeight":"558.60"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By blocking the angiotensin II receptor, olmesartan medoxomil causes vasodilation and reduces peripheral resistance, leading to decreased blood pressure. This mechanism is particularly beneficial in patients with hypertension, as it helps to reduce the risk of cardiovascular events such as heart attacks and strokes.","oneSentence":"Olmesartan medoxomil is an angiotensin II receptor antagonist that blocks the action of angiotensin II, a potent vasoconstrictor, thereby lowering blood pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:24:00.097Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"}]},"trialDetails":[{"nctId":"NCT00791258","phase":"PHASE4","title":"A Dose Escalation Study of a Combination Antihypertensive Drug in the Treatment of Various Groups of Patients Who do Not Respond to Single Drug Treatment of Their High Blood Pressure","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2008-11","conditions":"Hypertension","enrollment":999},{"nctId":"NCT00891267","phase":"PHASE3","title":"Effect of Two Doses of Olmesartan Medoxomil and Amlodipine on Vascular Markers in Hypertensive Patients With Metabolic Syndrome","status":"COMPLETED","sponsor":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","startDate":"2008-10","conditions":"Metabolic Syndrome, Hypertension","enrollment":60},{"nctId":"NCT00676845","phase":"PHASE3","title":"Study to Determine if Olmesartan Medoxomil Has the Potential to Benefit the Cardiovascular System in Terms of Arterial Protection","status":"COMPLETED","sponsor":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","startDate":"2008-08","conditions":"Metabolic Syndrome, Hypertension","enrollment":133},{"nctId":"NCT00151775","phase":"PHASE2, PHASE3","title":"Assessment of Efficacy and Safety of Olmesartan Medoxomil in Children and Adolescent Patients With High Blood Pressure","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2005-05","conditions":"Hypertension","enrollment":362},{"nctId":"NCT01692301","phase":"PHASE2","title":"Study of the Safety and Efficacy of LCZ696 on Arterial Stiffness in Elderly Patients With Hypertension","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-12","conditions":"Hypertension","enrollment":454},{"nctId":"NCT00996281","phase":"PHASE3","title":"Safety and Tolerability of Azilsartan Medoxomil Plus Chlorthalidone Compared to Olmesartan Medoxomil Plus Hydrochlorothiazide in Participants With Essential Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2009-10","conditions":"Essential Hypertension","enrollment":837},{"nctId":"NCT00846365","phase":"PHASE3","title":"Efficacy and Safety of Azilsartan Medoxomil Plus Chlorthalidone in Participants With Moderate to Severe Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2009-03","conditions":"Essential Hypertension","enrollment":1085},{"nctId":"NCT01033071","phase":"PHASE3","title":"Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Moderate to Severe Hypertension.","status":"COMPLETED","sponsor":"Takeda","startDate":"2010-01","conditions":"Essential Hypertension","enrollment":1071},{"nctId":"NCT00914524","phase":"PHASE2","title":"Study of Olmesartan Medoxomil (CS-866) in Patients With Chronic Glomerulonephritis or Diabetic Nephropathy","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2005-01","conditions":"Chronic Glomerulonephritis, Diabetic Nephropathy","enrollment":49}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Olmesartan medoxomil tablets high dose","genericName":"Olmesartan medoxomil tablets high dose","companyName":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","companyId":"daiichi-sankyo-europe-gmbh-a-daiichi-sankyo-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Olmesartan medoxomil is an angiotensin II receptor antagonist that blocks the action of angiotensin II, a potent vasoconstrictor, thereby lowering blood pressure. Used for Hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}